| Literature DB >> 22410304 |
Apostolos Bossios1,2, Maria Theodoropoulou1,3, Lucie Mondoulet4,5, Neil M Rigby6, Nikolaos G Papadopoulos1, Hervé Bernard4, Karine Adel-Patient4, Jean-Michel Wal4, Clare En Mills6, Photini Papageorgiou1.
Abstract
BACKGROUND: Cow's milk (CM) allergy affects about 2% of infants. The allergenicity of dietary proteins, including those from CM, has been related to their digestibility although the generality of the link and its causality remains to be demonstrated. In this study we use an in vitro digestion system, to investigate the digestibility of β-lactoglobulin (blg) during gastrointestinal transit and to assess the impact of this process on blg allergenic reactivity in CM allergic children.Entities:
Year: 2011 PMID: 22410304 PMCID: PMC3339358 DOI: 10.1186/2045-7022-1-6
Source DB: PubMed Journal: Clin Transl Allergy ISSN: 2045-7022 Impact factor: 5.871
Figure 1Characterization of blg digesta. A) phase 1 digestion: Lane 1 BLG @ 5 mg/ml, +PC (phosphatidyl choline) +E (enzyme). Lane 2 BLG @ 0.5 mg/ml, +PC +E. Lane 3 BLG @ 5 mg/ml, +PC -E. Lane 4 BLG @ 0.5 mg/ml, +PC -E. Lane 5 BLG @ 5 mg/ml, -PC +E. Lane 6 BLG @ 0.5 mg/ml, -PC +E. Lane 7 BLG @ 5 mg/ml, -PC -E. Lane 8 BLG @ 0.5 mg/ml, -PC -E. Lane 9 BLG @ 5 mg/ml. B) phase 1+2 digestion: Lane 1, BLG @ 5 mg/ml, +PC (phosphatidyl choline) +E (enzyme). Lane 2 BLG @ 0.5 mg/ml, +PC +E. Lane 3 BLG @ 5 mg/ml, +PC -E. Lane 4 BLG @ 0.5 mg/ml, +PC -E. Lane 5 BLG @ 5 mg/ml, -PC +E. Lane 6 BLG @ 0.5 mg/ml, -PC +E. Lane 7 BLG @ 5 mg/ml, -PC -E. Lane 8 BLG @ 0.5 mg/ml, -PC -E. Lane 9 BLG @ 5 mg/ml. Lane 10 BLG @ 0.5 mg/ml. Asterisk (*) denotes BLG SDS resistant dimmer, triangle (Δ) denotes Phosphatidyl choline.
Levels of intact native blg concentrations in different digesta determined by sandwich ELISA
| Intact blg (mg/ml) | Residual blg | ||||
|---|---|---|---|---|---|
| Digestion | Control | Enzyme | Control | Enzyme | |
| 5.0 | 3.4 | 100 | 70 | ||
| 4.7 | 3.2 | 100 | 68 | ||
| 5.0 | 0.14 | 100 | 3 | ||
| 4.5 | 3.0 | 100 | 66 | ||
Control digestions were performed without the addition of proteases.
Figure 2IgE immunoreactivity of blg digesta. Analysis of the immunoreactivity of blg digesta by EAST inhibition using serum from a CM allergic child. A: phase 1, B: phase 1+2.
Figure 3. Effect of gastric (phase 1) and gastro-duodenal (phase 1+2) digestion on the ability of blg to activate basophils (A) or stimulate proliferation of PBLCs (B) from CMA children. Results are expressed as mean values ± SEM. AI: Activation Index representing the ratio between the percentages (%) of cells expressing CD63 on their surface incubated in the presence of digesta and the percentage (%) of cells expressing CD63 incubated in the absence of digesta. PI: Proliferation Index representing the ratio between the percentage (%) of cells expressing PCNA on their surface cultured in the presence of digesta and the percentage (%) of cells expressing PCNA cultured in the absence of digesta. PC:phosphatidylcholine. * P < 0.05.
Figure 4. Effect of phase 1 and phase 1+2 blg digestion on SPT reactivity of CM allergic children. Results are expressed as mean values ± SEM. PC:phosphatidylcholine. * P < 0.05.
Figure 5Titration of in vitro produced blg digesta. An assessment of dose-responses of in vitro produced phase 1 and phase 1+2 blg digesta and their effect on basophil activation (A), PCNA reactivity (B) and SPT reactivity (C) of CM allergic children. AI and PI as indicated in figure 3.